A Phase 2 Randomized Double-Blind Placebo-Controlled Crossover Study Assessing The Ability Of Esreboxetine (PNU-165442g) To Improve Cognitive Function In Fibromyalgia Patients.
Phase of Trial: Phase II
Latest Information Update: 15 Jul 2009
At a glance
- Drugs Esreboxetine (Primary)
- Indications Fibromyalgia
- Focus Pharmacodynamics
- Sponsors Pfizer
- 15 Jul 2009 Actual patient number (89) added as reported by ClinicalTrials.gov.
- 15 Jul 2009 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
- 15 Jul 2009 Status changed from discontinued to completed as reported by ClinicalTrials.gov.